PTC Therapeutics Inc PTCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PTC Therapeutics Says FDA to Review Proposed PKU Treatment
-
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
-
PTC Therapeutics' Huntington's Treatment Gets FDA Fast Track Designation
-
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
-
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Trading Information
- Previous Close Price
- $36.05
- Day Range
- $35.91–37.36
- 52-Week Range
- $17.53–40.69
- Bid/Ask
- $31.15 / $36.43
- Market Cap
- $2.80 Bil
- Volume/Avg
- 736,838 / 598,485
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 995
- Website
- https://www.ptcbio.com
Comparables
Valuation
|
Metric
|
PTCT
|
SWTX
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.37 |
Price/Book Value | — | 4.38 | 3.57 |
Price/Sales | 3.08 | 26.25 | 4.05 |
Price/Cash Flow | — | — | 16.58 |
Price/Earnings
PTCT
SWTX
EXEL
Financial Strength
|
Metric
|
PTCT
|
SWTX
|
EXEL
|
|---|---|---|---|
Quick Ratio | 2.10 | 7.49 | 4.05 |
Current Ratio | 2.23 | 7.91 | 4.27 |
Interest Coverage | −2.15 | — | — |
Quick Ratio
PTCT
SWTX
EXEL
Profitability
|
Metric
|
PTCT
|
SWTX
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | −15.67% | −32.86% | 14.82% |
Return on Equity (Normalized) | — | −37.78% | 19.05% |
Return on Invested Capital (Normalized) | −102.66% | −42.13% | 14.99% |
Return on Assets
PTCT
SWTX
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zdftpksg | Fqqb | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ssvssgnh | Qnvbk | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mzrxwkchw | Xtfytq | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Svqwfvmq | Xgsbm | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Hztlzwpq | Rthc | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Mlqpprmw | Bgcy | $28.3 Bil | |||
| Moderna Inc
MRNA
| Hpvyjbznd | Rxx | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Cxztcwv | Cghtk | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kxpybzvpb | Kyxpsz | $13.3 Bil | |||
| Incyte Corp
INCY
| Qwbqywfgq | Dslmp | $13.0 Bil |
United States